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6Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
7Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Portugal Faculty of Medicine University of Porto,
Department of Biomedicine, Porto, Portugal
8Center for Health Technology and Services Research (CINTESIS); Faculdade de Medicina da Universidade do Porto,
Departamento de Medicina da Comunidade Informação e Decisão em Saúde (MEDCIDS); Faculdade de Medicina da Universidade
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Background. High rates of opioid use for chronic noncancer pain (CNCP) have been reported worldwide, despite its association
with adverse events, inappropriate use, and limited analgesic effect. Opioid-induced constipation (OIC) is the most prevalent and
disabling adverse effect associatedwith opioid therapy. Our aim was to assess the incidence, health related quality of life (HRQOL),
and disability in OIC patients. Methods. A prospective cohort study was performed, with 6 months of follow-up, of adult CNCP
patients consecutively admitted in 4multidisciplinary pain clinics (MPC). Demographic and clinical data have been collected. Brief
Pain Inventory (BPI) and Short version of TreatmentOutcomes in Pain Survey (S-TOPS)were used tomeasure functional outcomes
and HRQOL. OIC was assessed using Bowel Function Index (BFI). Results. 694 patients were recruited. OIC prevalence at baseline
was 25.8%. At 6 months, OIC incidence was 24.8%. Female gender (OR = 1.65, 𝑝 = 0.039), opioid therapy (OR 1.65, 𝑝 = 0.026), and
interference pain score on BPI (OR 1.10, 𝑝 = 0.009) were identified as OIC independent predictors. OIC patients presented higher
disability and pain interference and severity scores. OIC patients reported less satisfaction with outcome (𝑝 = 0.038). Discussion.
Constipation is a common adverse event among opioid users with major functional and quality of life impairment. These findings
emphasise the need of OIC adequate assessment and management.
1. Introduction
Chronic pain is amajor public healthcare problemworldwide
[1]. It has an estimated prevalence of 20% in the European
population and is an important cause of quality of life
impairment and substantial burden in healthcare systems [2–
4]. Opioids may be a safe and reliable therapeutic option
for moderate or severe chronic pain treatment, but their
adequate prescription requires suitable patients’ selection,
clinicians’ training, and patients’ education. Indeed, opioid
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use in chronic noncancer pain (CNCP) treatment is recom-
mended in several guidelines [5–7], and high prescription
rates were observed in several countries of Europe and the
United States in the last decade [8–10], although there has
been a decreasing trend in prescription rates since 2011 [10,
11].
Opioid use is associated with adverse effects development
such as gastrointestinal disorders, neuroendocrine dysfunc-
tion, osteoporosis, immunosuppression, cognitive disorders,
drowsiness, respiratory depression, physical dependence,
hyperalgesia, and addiction [12–16]. Therefore, opioid pre-
scription requires adequate and regular clinical supervision
in order to monitor their efficacy and safety.
Gastrointestinal disorders, including constipation, nau-
sea, vomiting, abdominal cramping, and bloating, are often
associated with opioid use and represent an important cause
of opioid withdrawal [17]. Opioid-induced constipation, a
type of secondary constipation [18], is the most prevalent
and disabling adverse effect associated with chronic opioid
therapy. There is no consensual definition in the literature
for OIC [19]. According to Gaertner et al., OIC is defined
as a “change from baseline in bowel habits and change in
defecation patterns after initiating opioid therapy, which is
characterized by any of the following: reduced frequency
of spontaneous bowel movements (BM), development or
worsening of straining to pass BMs, a sense of incomplete
rectal evacuation, and harder stool consistency” [20]. One
useful and reliable tool in clinical setting for OIC diagnosis
is the Bowel Function Index (BFI), a self-reported patient
questionnaire, with 3 variables: ease of defecation, feeling of
incomplete evacuation, and personal judgment of constipa-
tion [21–23].
OIC prevalence is estimated to be as high as 40-64%
in CNCP patients on opioid therapy. Moreover, OIC is the
most common secondary cause of constipation to which
patients do not become tolerant [24]. This prevalence may
vary according to the type and dose of opioid prescribed,
route of administration, and treatment duration. Morphine
seems to be the opioid with the highest associated risk of
OIC, while transdermal preparations of Buprenorphine and
Fentanyl are associated with lower risk [25]. However, the
prevalence may also vary due to differences in clinical super-
vision onOIC development and prophylactic laxative therapy
prescription, as well as variability in patient’s perception of
their constipation symptoms [19, 26–28].
In clinical practice, it is important to keep a high index
of suspicion concerning OIC since many patients do not feel
comfortable to discuss this problem with their doctor [29].
According to the literature, the economic impact of OIC
among long-term opioid users is significant [30]. Therefore,
effective therapies on OIC are needed in order to reduce OIC
related costs and improve patient’s quality of life [30, 31].
Moreover, CNCP patients have a high prevalence of associ-
ated depression, occurring in up to 50% of these patients [32],
and depression is also a prevalent condition associated with
functional constipation. Because OIC has a similar clinical
presentation as functional constipation, it is important for
clinicians to be aware of functional constipation prevalence
in this specific population when considering opioid therapy
prescription. Adequate prophylactic measures and a high
index of suspicion may contribute to a higher success on OIC
symptoms management [17, 32, 33].
The primary aim of this study was to assess and esti-
mate the incidence of OIC, health related quality of life
and disability in CNCP patients followed in Chronic Pain
Clinics. Secondary aims include assessment of pain clinical
characteristics, analgesic prescription, laxative therapy, and
interference in activities of daily living among OIC patients.
2. Methods
2.1. Study Design. A prospective cohort study with 6 months
of follow-up was performed in 4 multidisciplinary pain
clinics (MPC). This study was conducted in accordance with
the Guideline for Good Clinical Practice of the International
Conference on Harmonization and the ethical principles of
the Declaration of Helsinki. The approvals from the National
Committee for Data Protection and from local Ethical Com-
mitteeswere obtained. All patients were informed of the study
details and signed an informed consent.
2.2. Patient Selection. Participants were recruited during
their first appointment in one of the MPC and were included
if they provided consent to participate, were 18 years or older,
and presented CNCP ≥ 3 months.
Patients with psychiatric or cognitive disorders that could
interfere with data collection, those physically or psycho-
logically unable to communicate, and those unable to speak
Portuguese were excluded.
2.3. DataCollection. Datawas collected in a face to face inter-
view with a trained interviewer at patient’s first consultation
in the MPC and through consultation of hospital records.
Patient follow-up contacts weremade by telephone by trained
interviewers at 1 week and 3 and 6 months. During this
period, data collection was complemented with consultation
and analysis of hospital records.
A structured questionnaire was used to collect the follow-
ing patients’ data: demographic characteristics, clinical and
pain characteristics, follow-up, pharmacological treatment
prescribed, daily activities pain interference, health related
quality of life (HRQOL), and clinical outcomes.The following
translated, culturally adapted, and validated instruments for
Portuguese population were used: Bowel Function Index
(BFI) questionnaire [22, 35]; Brief Pain Inventory [BPI] [36,
37], and Short version of the Treatment Outcomes in Pain
Survey (S-TOPS) [38, 39].
The BFI self-report questionnaire consists of three ques-
tions about constipation symptoms in the last 7 days: ease
of defecation, feeling of incomplete evacuation, and personal
judgment of constipation. Each item is scored from 0 to
100 by the patient according to the last 7 days. The BFI
score is calculated as the mean of the three items scores
[21, 23]. The cut-off definition BFI score for OIC is 28.8
points [34]. In caseswere constipationwas present at baseline,
OIC was considered in patients under opioid therapy that
presented a clinically significant change ≥ 12 points in BFI
score, according to the criteria defined by Rentz et al. (Rentz,
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2009 #2) or an increase in the dosage of previously used
laxatives.
The BPI questionnaire is a self-report questionnaire mea-
suring both the intensity of pain (sensory dimension) and
interference of pain in the patient’s life (reactive dimension).
Each item is rated in a scale from 0 to 10. Pain severity and
interference scores are calculated by the mean of the answers
on each dimension of the questionnaire [35, 37, 40].
The S-TOPS questionnaire was used to assess changes in
OIC related quality of life (QOL) from baseline to 6 months.
S-TOPS is composed by 7 validated independent subscales
with a total of 29 items: (1) Pain Symptom; (2) Physical
Disability-Lower Body; (3) Physical Disability-Upper Body;
(4) Family/Social Disability; (5) Role Emotional Disability;
(6) Patient Satisfaction with Care; and (7) Patient Satisfac-
tion with Outcomes. Each subscale score from S-TOPS is
expressed from 0 (“no pain/disability”) to 100 (“maximum
pain/disability”). The satisfaction with care and satisfaction
with outcomes subscales are inverted, with 0 representing “no
satisfaction” and 100 representing “maximum satisfaction”.
The mean of the answers in each subscale was calculated
[41].
Pain aetiology classification was conducted according to
IASP Taskforce on Pain Classification for ICD-11 [42].
2.4. Outcome Assessment. The primary outcome assessment
of our study was OIC incidence at 6 months, as previously
defined, and OIC related QOL change from baseline to
6 months concerning physical disability, family and social
disability, role emotional disability, and patient satisfaction
with outcomes. Secondary outcomes included change from
baseline in the following: pain severity and pain interference
scales of the BPI, opioid consumption, laxative prescription,
and general health status perception.
2.5. Statistical Analysis. We described our population con-
sidering OIC prevalence at baseline and pain clinical char-
acterization. The primary analysis was stratified on OIC
incidence at 6 months of follow-up. Descriptive statistics of
patient characteristics and clinical variables are presented as
frequencies with percentages (%), median with interquar-
tile range or mean with standard deviation [43] when
appropriate. Nonparametric and parametric tests were per-
formed for comparisons between numerical variables accord-
ing their distribution and chi-squared test for categorical
variables.
A 𝑝-value ≤ 0.05 was considered significant for all tests.
Multivariate logistic regression analysis was performed.
Univariate predictors of outcome with a 𝑝-value <0.10 were
selected for multivariate logistic regression analysis with
stepwise backward elimination. The dependent variable was
OIC and possible predictors were used as independent
variables. We have evaluated goodness of fit of the logistic
regression model using the Hosmer-Lemeshow test and
receiver operating characteristic (ROC) curve to evaluate its
predictive and discriminative power.
Statistical analysis was performed using the Statisti-
cal Package for the Social Sciences version 24.0 (SPSS,
USA).
3. Results
3.1. Prevalence and Incidence of OIC. 694 patients withCNCP
diagnosis were recruited. The general characteristics of the
cohort are described in Table 1.
OIC prevalence at baseline was 25.8% (𝑛 = 174; BFI
median 18.9 ± 30.9). At their first consultation, OIC patients
were mostly >75 years old (𝑛 = 29, 33.0%), female (𝑛 = 131,
75.3%), with a low level of education (1-4 years; 𝑛 = 94,
54.3%), and with a median BMI of 26.3 ± 3.8. 63.2% of OIC
patients (𝑛 = 110) were prescribed with weak opioids and
36.8% (𝑛 = 54) with strong opioids. Most OIC patients were
not prescribed with laxative therapy (𝑛 = 162; 93.1%) before
their first consultation at MPC. At six-month follow-up, OIC
was persistent in 51.7% (𝑛 = 90) of patients having OIC at
baseline and resolved in 48.3% (𝑛 = 84) of them. There were
no significant differences among these two subgroups except
concerning prescription of laxative therapy in persistent OIC
patients (𝑝 < 0.001) (Table 2).
At 6 months, OIC prevalence was 32.0% (𝑛 = 216), and
OIC incidence was 24.8% (𝑛 = 126; BFI mean 18.8 ± 28.5).
OIC patients at 6 months were mostly 40-65 years old (𝑛 =
60, 35.9%), female (𝑛 = 134, 80.2%), with low levels of
education (1-4 years; 𝑛 = 94, 56.3%), and with a median
BMI of 26.9 ± 5.1. There was a significant association among
OIC development and opioid prescription (𝑝 = 0.034), but
there were no significant differences among strong and weak
opioids prescriptions in these patients. Patients with OIC had
a higher prescription rate of laxative therapy (𝑝 < 0.001).
Although other adverse drug reactions [44] associated
with opioids were not our primary focus, we obtained data
regarding other ADR, at 6 months, for 145 patients. Among
those, the most frequently reported ADRs associated with
opioids, besides OIC, were nausea and vomiting (27%), rash
(11%), somnolence/sleepiness (10%), dizziness (10%), and
pruritus (9%).
3.2. Clinical Characteristics, Severity, and Interference of Pain
in OIC Patients. Pain characteristics are described in Table 4.
Compared to non-OIC patients, OIC patients had longer
pain duration and presented more often pain at cervical
region, lumbar region, upper limbs, and lower limbs, both at
baseline and at 6 months of follow-up. More frequent pain
aetiologies were chronic musculoskeletal pain and chronic
neuropathic pain. However, these were not statistically dif-
ferent from non-OIC patients except for pain location at
cervical region (baseline and 6 months) and upper limb
(baseline). There were no significant differences in pain
severity and interference scores at baseline among OIC
and non-OIC patients (Figure 1). However, at baseline OIC
patients reported statistically significant higher interference
pain scores in general activity, mood, walking ability, normal
work, relations with other people, sleep, and enjoyment of life
(𝑝 < 0.05).
At 6-month follow-up, OIC patients presented significant
higher pain severity scores (5.5 P25-P75 4.0-7.0 versus 5.0
P25-P75 3.2-6.5, 𝑝 = 0.021) and higher pain interference
scores (5.9 P25-P75 4.0-7.3 versus 4.9 P25-P75 2.1-7.0, 𝑝 <
0.001) in all domains (Figure 2).
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Table 1: General characteristics of CNCP patients at baseline.
Variable No Constipation Constipation
Total 674 (100%) 500 (74.2%) 174 (25.8%)
Age, years
18-45 151 110 (22.0%) 41 (23.6%)
45-60 214 162 (32.4%) 52 (29.9%)
60-75 221 169 (33.8%) 52 (29.9%)
>75 88 59 (11.8%) 29 (16.7%)
Gender
Female 488 357 (71.4%) 131 (75.3%)
Male 186 143 (28.6%) 43 (24.7%)
BMI 27.0 (±5.20) 27.1 (±5.20) 26.5 (±5.20)
Education level
No education 19 12 (2.4%) 7 (4.0%)
1-4 years (basic 1st cycle) 340 246 (49.2%) 94 (54.3%)
5-9 years (basic 2nd and 3rd cycles) 163 127 (25.4%) 36 (20.8%)
10-12 years (secondary) 78 60 (12.0%) 18 (10.4%)
More than 12 years(higher) 73 55 (11.0%) 18 (10.4%)
Opioid therapy 402 228 (56.7%) 174 (43.2%)
Analgesic prescription
Non-opioid 213 163 (32.6%) 50 (28.7%)
Weak opioid 339 229 (45.8%) 110 (63.2%)
Strong opioid 126 62 (12.4%) 64 (36.8%)
Laxatives use 24 12 (15.8%) 12 (30.8%)
Current depressive disorder on treatment 139 97 (20.8%) 42 (25.8%)
OIC: opioid-induced constipation; BMI: bodymass index; data are presented as 𝑛 (%) except BMIwhich is presented asmean ± standard deviation. Proportions
are calculated as column proportions.
5,3 (3,5-6,5) 5,1 (2,6-7,1)5,5 (3,7-6,7)
5,6 (3,1-7,0)
Pain Severity Pain Interference
BASELINE
No OIC
OIC
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1
2
3
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10
Figure 1: Brief Pain Inventory questionnaire at baseline. Data are
presented asmedian (interquartile range).𝑃 values are derived from
T test (pain severity) andMann-Whitney U test (pain interference),
3.3. Outcomes Assessment of OIC and Related Quality of
Life (QoL). At baseline, OIC patients reported significantly
higher disability in physical lower function (59.8±30.9 versus
53.9 ± 32.5, 𝑝 = 0.028), physical upper function (34.0 ± 24.0
versus 26.7 ± 21.5, 𝑝 < 0.001), and family/social disability
(41.6 ± 24.9 versus 35.5 ± 24.7, 𝑝 < 0.001) (Figure 3), and
32.9% (𝑛 = 222) considered that their health was poor.
At 6 months, OIC patients reported significantly higher
disability in all subscales of S-TOPS questionnaire except
physical upper function: pain severity (62.3 ± 20.9 versus
5,0 (3,2-6,5) 4,9 (2,1-7,0)
5,5 (4,0-7,0) 5,9 (4,0-7,3)
6 MONTHS
∗ ∗∗
Pain Severity Pain Interference
NO OIC
OIC
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
8,0
9,0
10,0
Figure 2: Brief Pain Inventory at 6 months. Data are presented as
median (interquartile range). 𝑃 values are derived from T test (Pain
severity) and Mann-Whitney U test (Pain interference). ∗𝑝 < 0.05,
∗∗𝑝 < 0.001.
55.8 ± 25.2, 𝑝 = 0.011), physical lower function (57.5 ±
31.1 versus 52.8 ± 33.7, 𝑝 = 0.026), family/social disability
(36.2±27.5 versus 28.8±26.8, 𝑝 = 0.005), and role emotional
disability (45.4 ± 34.5 versus 53.9 ± 32.5, 𝑝 = 0.028). OIC
patients reported significantly less satisfaction with outcomes
than non-OIC patients (54.5 ± 22.0 versus 56.0 ± 26.1, 𝑝 =
0.038) (Figure 4). At 6 months of follow-up, 38.0% (𝑛 = 256)
of OIC patients considered that their health was poor.
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Table 2: Follow-up at 6 months of patients with OIC at baseline.
6 Months Follow-up of OIC patients at baseline
Variable Previous OIC (OIC absent at 6months)
Current OIC (OIC still present at 6
months) 𝑃 value
Total 84 (48.3%) 90 (51.7%)
Age, years 0.349a
18-45 23 (27.4%) 18 (20.0%)
45-60 27 (32.1%) 25 (27.8%)
60-75 20 (16.7%) 32 (35.6%)
>75 14 (48.3%) 15 (16.7%)
Gender
Female 60 (71.4%) 71 (78.9%) 0.293a
Male 24 (28.6%) 19 (21.1%)
BMI 27.15 26.49 0.178b
Mean [34]; (±5.20) (±5.20)
Education level 0.047a
No education 4 (4.8%) 3 (3.3%)
1-4 years (basic 1st cycle) 40 (48.2%) 54 (60.0%)
5-9 years (basic 2nd and 3rd cycles) 15 (18.1%) 21 (23.3%)
10-12 years (secondary) 12 (14.5%) 6 (6.7%)
More than 12 years(higher) 12 (14.5%) 6 (6.7%)
Opioid therapy 0.409a
Weak opioid 43 (51.2%) 50 (55.6%)
Strong opioid 41 (48.8%) 40 (44.4%)
Laxatives use 0 (0%) 19 (100%) <0.001a
Current depressive disorder on
treatment 20 (24.4%) 14 (27.2%) 0.686
OIC: opioid-induced constipation; BMI: bodymass index. Data are presented as 𝑛 (%) except BMIwhich is presented asmean± standard deviation. Proportions
are calculated as column proportions. 𝑃 values are derived from (a) x2 comparisons; (b) 𝑇 test.
69,8
53,9
26,7
35,5 36,9 36,2
72,9
59,8
34,0
41,6 41,7 36,8
Pain
Severity
PD-LB PD-UB Fam-Soc
Disab
Role-Emot
Disab
SatOutcome
BASELINE
∗
∗∗
∗∗
0,0
10,0
20,0
30,0
40,0
50,0
60,0
70,0
80,0
90,0
100,0
No OIC
OIC
Figure 3: Short-Treatment Outcomes in Pain Survey (S-TOPS)
questionnaire at baseline. OIC: opioid-induced constipation; PD-
LB: physical Disability lower body; PD-LB: physical disability upper
body; FAM-SOCDISAB: family and social disability; ROLE-EMOT
DISAB: role emotional disability; SATOUTCOME: satisfaction with
outcomes. Data are presented as median of each subscale. 𝑃 values
are derived from Mann-Whitney U test comparisons. ∗𝑝 < 0.05,
∗∗𝑝 < 0, 001.
55,8 52,8
76,1
28,8
33,3
56,0
62,3 57,5
66,1
36,2
45,4
54,5
6 MONTHS
∗
∗
∗
∗
∗∗
∗
0,0
10,0
20,0
30,0
40,0
50,0
60,0
70,0
80,0
90,0
100,0
Pain
Severity
PD-LB PD-UB Fam-Soc
Disab
Role-Emot
Disab
SatOutcome
NO OIC
OIC
Figure 4: Short-Treatment Outcomes in Pain Survey (S-TOPS)
questionnaire at 6 months. OIC: opioid-induced constipation; PD-
LB: physical disability lower body; PD-LB: physical disability upper
body; FAM-SOC DISAB: family social disability; ROLE-EMOT
DISAB: role emotional disability; SATOUTCOME: satisfaction with
outcomes. Data are presented as median of each subscale. 𝑃 values
are derived from Mann-Whitney U test comparisons. ∗𝑝 < 0.05,
∗∗𝑝 < 0.001.
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Table 3: OIC incidence at 6 months.
OIC Incidence at 6 months of follow-up
Variable No Constipation Constipation 𝑃 value
Age, years 0.171a
18-45 123 (24.3%) 28 (16.8%)
45-60 154 (30.4%) 60 (35.9%)
60-75 167 (32.9%) 54 (32.3%)
>75 63 (12.4%) 25 (15.0%)
Gender
Female 354 (69.8%) 134 (80.2%) 0.009a
Male 153 (30.2%) 33 (19.8%)
BMI 27.33 (5.50) 26.87 (5.10) 0.357b
Education level 0.562a
No education 15 (3.0%) 4 (2.4%)
1-4 years (basic 1st cycle) 246 (48.6%) 94 (56.3%)
5-9 years (basic 2nd and 3rd cycles) 127 (25.1%) 36 (21.6%)
10-12 years (secondary) 61 (12.1%) 17 (10.2%)
More than 12 years (higher) 57 (11.3%) 16 (9.6%)
Opioid therapy 0.034a
Yes 338 (72.8%) 126 (75.4%)
No 169 (80.5%) 41 (24.6%)
AnalgesicTherapy 0.087a
Non-opioid 168 (80.4%) 41 (24.6%)
Weak opioid 233 (71.9%) 91 (54.5%)
Strong opioid 104 (74.8%) 35 (21.0%)
Laxatives use 2 (100%) 51 (100%) <0.001a
Depressive disorder 102 (21.4%) 37 (24.0%) 0.504a
OIC: opioid-induced constipation; BMI: bodymass index. Data are presented as 𝑛 (%) except BMIwhich is presented asmean± standard deviation. Proportions
are calculated as column proportions. 𝑃 values are derived from (a) x2; (b) 𝑇 test comparisons.
3.4. Predictors ofOIC at 6Months. Tables 3 and 4 and Figure 2
present factors associated with OIC incidence development
at 6 months. Gender (𝑝 = 0.009), opioid use (𝑝 = 0.034),
BPI severity score (𝑝 = 0.021), and BPI interference score
(𝑝 < 0.001) are significantly associated with OIC. Taking
into account the available literature [28, 40, 41], we decided
to include depressive disorders diagnosis in our multivariate
regression analysis model.
Table 5 describes independent predictors of OIC at 6
months identified in amultivariate logistic regression analysis
with stepwise backward elimination. In our multivariate
model, opioid therapy (OR 1.65, 𝑝 = 0.026), female gender
(OR 1.65, 𝑝 = 0.039), and higher interference pain score (OR
1.10, 𝑝 = 0.009) are independent predictors of higher risk of
OIC at 6 months. Our model had a good predictive power
(Hosmer and Lemeshow test: 𝑝 = 0.107) and a moderate
discriminative power (AUC 0,678, 𝑝 < 0.001).
4. Discussion
Opioid-induced constipation is a prevalent and debilitating
condition with a significantly high impact in patient’s quality
of life and well-being. OIC has an estimated prevalence of
15-90 % in chronic noncancer pain patients. Our estimated
prevalence of 25.8% at baseline and 32.0% at 6-month follow-
up is in accordance with previous data [19, 27]. Indeed,
in the last decades there has been an increment of opioid
prescription for chronic noncancer pain management that
may explain high OIC prevalence among this specific pop-
ulation [6, 15, 45]. Long-term exposure, high opioid doses
and absence of laxative therapy are some of the conditions
associated with OIC development [17, 27].
Chronic noncancer pain is more prevalent in female
gender and with increasing age [6]. Therefore, a similar
demographic data in the OIC population was expected [46,
47].
In our study, at 6 months OIC patients reported higher
pain severity score (𝑝 = 0.021) and higher pain interference
score (𝑝 < 0.001). These results are in accordance with the
statistically significant association with opioid prescription in
these patients (𝑝 = 0.034). Indeed, it is expected that patients
with more severe pain are more often prescribed with opioids
and for longer periods, and, therefore, present a higher
risk of OIC development. Several studies have reported the
association of OIC with the burden of opioid prescription in
CNCP in the last decades [1, 48, 49].
OIC is the most prevalent adverse effect associated with
opioid use and has severe impact on patient’s quality of life
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Table 4: Pain characteristics.
Pain Characteristics Baseline 6 Months
Total Noconstipation Constipation P value
No
Constipation Constipation P value
Pain duration Pain duration inyears 4.0 (2.0-12.0) 4.0 (2.0-13.0) 5.0 (2.0-10.5) 0.207
c 4.0 (2.0-12.0) 4.7 (2.0-14.0) 0.782b
Pain location
Head 67 (65.0%) 67 (65.0%) 36 (35.0%) 0.021a 69 (67.0%) 34 (33.0%) 0.931a
Face 26 (61.9%) 26 (61.9%) 16 (38.1%) 0.060a 28 (66.7%) 14 (33.3%) 0.921a
Cervical region 172 (68.5%) 172 (68.5%) 79 (31.5%) 0.010a 156 (62.2%) 95 (37.8%) 0.028a
Dorsal region 41 (64.1%) 41 (64.1%) 23 (35.9%) 0.052a 46 (71.9%) 18 (28.1%) 0.485a
Lumbar region 292 (73.7%) 292 (73.7%) 104 (26.3%) 0.324a 265 (66.9%) 131 (33.1%) 0.803a
Abdominal region 21 (73.8%) 21 (73.8%) 11 (26.2%) 0.954a 28 (66.7%) 14 (33.3%) 0.921a
Upper Limb 240 (70.4%) 240 (70.4%) 101 (29.6%) 0.022a 226 (66.3%) 115 (31.5%) 0.566a
Lower Limb 314 (72.5%) 314 (72.5%) 119 (27.5%) 0.185a 294 (67.9%) 139 (33.6%) 0.732a
Pain aetiology
Chronic primary
pain 50 (7.4%) 32 (64.0%) 18 (36.0%) 0.087
a 18 (43.9%) 23 (56.1%) 0.008a
Chronic
postsurgical and
posttraumatic pain
92 (13.6%) 66 (71,7%) 26 (28.3%) 0.564a 47 (62.7%) 28 (37.3%) 0.813a
Chronic
neuropathic pain 170 (25.2%) 128 (75.3%) 42 (24.7%) 0.702
a 99 (67.8%) 47 (32.2%) 0.926a
Chronic headache
and orofacial pain 15 (2.2%) 6 (40.0%) 9 (60.0%) 0.002
a 7 (58.3%) 5 (41.7%) 0.581a
Chronic visceral
pain 26 (3.9%) 15 (57.7%) 11 (42.3%) 0.050
a 14 (63.6%) 8 (36.4%) 0.833a
Chronic
musculoskeletal
pain
254 (37.7%) 183 (72%) 71 (28.0%) 0.324a 249 (69.9%) 107 (30.1%) 0.310a
Data are presented as 𝑛 (%) except pain duration which is presented as median (interquartile range). Proportions are calculated as row proportions. 𝑃 values
are derived from (a) x2 comparisons; (b) 𝑇 test; (c) Mann-Whitney 𝑈 test.
and ability to perform daily life activities and work [27,
50]. OIC results from opioid action on mu-opioid receptors
in the gastrointestinal tract that induces delayed gastric
emptying, decreased bowel movements, increased intestinal
fluids absorption, and increased anal sphincter tone [17].
However, opioids may present different effects depending on
their location in the gastrointestinal tract. For instance, there
is tolerance development for mu-opioid receptor actions for
all gastrointestinal tract except for colon [51]. Therefore,
while other gastrointestinal disorders tend to disappear in
long-term opioid exposure, constipation is a persistent and
debilitating side effect that must be appropriately treated [51,
52]. Moreover, OIC is such a distressing adverse event that, as
a consequence, some patients prefer to reduce or discontinue
their opioid therapy and be in pain rather than experiencing
severe constipation.
OIC symptoms management is challenging and often
with unsatisfactory response to the available therapeu-
tics. OIC treatment encompasses either nonpharmacological
approaches (dietary fibre, fluid intake, and physical activity)
or nonspecific pharmacological approaches with laxatives
use (stimulants, softeners, bulk forming, and enemas) and
prokinetics. However, even with these therapeutic measures
many patients do not have significant OIC symptoms relief.
LoCasale et al. reported in a prospective longitudinal study
of 489 OIC noncancer pain patients, a high rate (48%)
of inadequate OIC relief despite adequate laxative therapy
prescribed [24]. Nowadays, new specific pharmacological
treatments with formulations containing peripherally act-
ing opioid antagonists such as methylnaltrexone bromide
and oxycodone/naloxone are available and may allow more
efficacy in OIC management without analgesia impairment
[26, 27, 53, 54]. However, in spite of the available recom-
mendations, early prescription of prophylactic measures such
as dietary fibre, fluid intake, physical activity, and laxative
use are not routine when starting an opioid prescription
[24, 27, 53]. In our study, the prescription rate of laxative
therapy at baseline was only of 6.9% (𝑛 = 12) in spite of
a prevalence of opioid use of 59.6% (𝑛 = 402) and an OIC
prevalence of 25.8% (𝑛 = 174). At 6 months of follow-up, our
prescription rate of laxative therapy in patients with persistent
OICwas still low (𝑛 = 19, 16.7%).These resultsmay reflect the
lack of awareness of healthcare professionals about the real
impact of OIC on patient’s quality of life andwell-being.More
efforts should be made to promote physician’s education on
OIC and increase safe and responsible opioid use.
At six-month follow-up, OIC patients reported signifi-
cantly higher disability in all subscales of S-TOPS question-
naire except physical upper function, which is consistent
with previous studies [20, 27]. Indeed, OIC has a severe and
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Table 5: Predictors of OIC at 6 months.
Crude OR
(95%CI)
Adjusted
OR
(95%CI)
Gender p = 0.010 p = 0.039
Female 1.76 (1.15-2.69) 1.65 (1.03-2.67)
Male 1 1
Current depressive
disorders 𝑃 = 0.50 -
1.16 (0.76-1.78)
Opioid therapy p = 0.036 p = 0.026
Yes 1.53 (1.03-2.28) 1.65 (1.06-2.56)
No 1 1
Severity Scale 𝑃 = 0.058 -
1.06 (1.00-1.13)
Interference Scale p = 0.001 p = 0.009
1.13 (1.06-1.21) 1.10 (1.02-1.19)
95% CI, 95% confidence interval; OR, odds ratio. Predictors of opioid
induced constipation defined by simple and multiple logistic regression;
crude and adjusted ORs for categories of demographic variables, opioid
therapy, and pain characteristics variables. Adjusted ORs were calculated
using multivariate logistic regression models. Multivariate model included
adjustment all variables with crude association measures with 𝑃 values <
0.1 in the univariate analysis. 𝑃 values for the omnibus tests evaluating the
significance of each predictor variable.
debilitating repercussion in the patients’ quality of life and
impairs their ability to perform daily life activities. In our
sample, OIC patients reported significantly less satisfaction
with outcomes than non-OIC patients (𝑝 = 0.034). LoCasale
et al. reported in another prospective observational study of
six-month follow-up that OIC patients despite adequate lax-
ative therapy prescription presented persistent constipation
and a small improvement in their quality of life and ability
to perform daily life activities [55]. This may lead patients
to reduce their opioid analgesic doses or even to opioid
withdrawal, which can compromise their CNCP manage-
ment. Another additional problem is related to patients’ long-
term exposure to opioid therapy and, therefore, to persistent
OIC symptoms and associated morbidity with significant
economic and societal costs [30, 31, 50, 56].
We have identified as independent predictors of incident
OIC at six-month follow-up, female gender, higher interfer-
ence pain score on BPI, and opioid therapy. The latter finding
was expected since opioid therapy is the major risk factor for
constipation development in CNCP patients. Moreover, this
risk increases with higher doses and longer exposure times
and varies with the type of opioid prescribed and route of
administration [19, 25, 27]. On the other hand, patients with
higher interference pain scores are those at increased risk of
being prescribed with opioids and in higher doses in order
to control their pain. Therefore, it was also expected that
patients with higher severity pain scores were also associated
with higher risk of OIC development at 6 months. However,
we have not found this association, which may be explained
by a more significant difference of interference than severity
pain scores among OIC and non-OIC patients. Taking into
account the higher prevalence of CNCP in female gender
and with increasing age, it is reasonable to expect that OIC
also presents a similar demographic characterization [25, 46].
To the best of our knowledge, there has been only one
publication concerning OIC predictors’ identification in a
sample of 2324 Italian patients on chronic pain treatment
[57]. According to the results of this study, opioid use, female
gender, and increasing age are risk factors for OIC develop-
ment. In cancer pain patients the risk of OIC development
seems to be higher when higher opioid doses are needed.
Our study has several strengths. It was an observational
prospective study with 6-month follow-up period regarding
OIC incidence, its predictive factors, functional outcomes,
and quality of life assessment based in the seven subscales
of the S-TOPS questionnaire following IMMPACT recom-
mendations [58]. We provided a detailed assessment based
on standardized and validated questionnaires. We believe
that our cohort is representative of the CNCP population
taking into account the fact that we included data from 4
different MPC. This study also presents some limitations. As
a prospective observational study, it may present selection
bias from losses of follow-up. To overcome this, we have
developed retention strategies since eligible patients have
consented and those who have continued for all duration of
the study in order to reduce our follow-up losses.
5. Conclusions
Opioid use is associated with the potential risk of adverse
effects development. OIC is the most prevalent side effect
and may negatively impact patients’ adherence to their
analgesic prescription. It is important to promote clinician’s
awareness on OIC since it is still a grossly underrecognized
and undertreated condition. A high index of suspicion in
high risk populations such as CNCP patients, utilization
of adequate diagnostic tools, and routine implementation
of prophylactic therapies such as laxatives prescription are
key measures to improve OIC management and reduce its
associated disability and costs.
Abbreviations
BFI: Bowel Function Index
BPI: Brief Pain Inventory
CNCP: Chronic noncancer pain
CI: Confidence interval
IASP: International Association for the Study of
Pain
ICD: International Classification of Diseases
IMMPACT: Initiative on Methods, Measurement, and
Pain Assessment in Clinical Trials
MCPC: Multidisciplinary Chronic Pain Clinics
OIC: Opioid-induced constipation
P25: 25th percentile
P75: 75th percentile
SD: Standard deviation
S-TOPS: Shortened Treatment Outcomes in Pain
Survey.
Pain Research and Treatment 9
Data Availability
The data used to support the findings of this study are
available from the corresponding author upon request.
Disclosure
This manuscript has been presented as a poster at Meeting
with Science and Technology in Portugal-Lisbon 2017.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Acknowledgments
This work was supported by intramural funds from the
Chair on Pain Medicine of the Faculty of Medicine, Uni-
versity of Porto, and by projects “Porto Neurosciences and
Neurologic Disease Research Initiative at i3S” (NORTE-01-
0145-FEDER-000008) and “NanoSTIMA” (NORTE-01-0145-
FEDER-000016), which are financed by the North Portugal
Regional Operational Programme (NORTE 2020), under
the Portugal 2020 Partnership Agreement, and through the
European Regional Development Fund (ERDF).
References
[1] D. S. Goldberg and S. J. McGee, “Pain as a global public health
priority,” BMC Public Health, vol. 11, no. 1, article 770, 2011.
[2] H. Breivik, E. Eisenberg, and T. O’Brien, “The individual and
societal burden of chronic pain in Europe: the case for strategic
prioritisation and action to improve knowledge and availability
of appropriate care,” BMC Public Health, vol. 13, no. 1, article
1229, 2013.
[3] L. F. Azevedo, A. Costa-Pereira, L. Mendonça, C. C. Dias, and
J. M. Castro-Lopes, “The economic impact of chronic pain: a
nationwide population-based cost-of-illness study in Portugal,”
European Journal of Health Economics, vol. 17, no. 1, pp. 87–98,
2016.
[4] L. F. Azevedo, A. Costa-Pereira, L. Mendonça, C. C. Dias,
and J. M. Castro-Lopes, “Chronic pain and health services
utilization: Is there overuse of diagnostic tests and inequalities
in nonpharmacologic treatment methods utilization?” Medical
Care, vol. 51, no. 10, pp. 859–869, 2013.
[5] C. R. Chapman, D. L. Lipschitz, M. S. Angst et al., “Opioid
pharmacotherapy for chronic non-cancer pain in the United
States: A research guideline for developing an evidence-base,”
The Journal of Pain, vol. 11, no. 9, pp. 807–829, 2010.
[6] T. O’Brien, L. L. Christrup, A. M. Drewes et al., “European Pain
Federation position paper on appropriate opioid use in chronic
pain management,” European Journal of Pain, vol. 21, no. 1, pp.
3–19, 2017.
[7] R. Chou, G. J. Fanciullo, P. G. Fine et al., “Clinical guidelines for
the use of chronic opioid therapy in chronic noncancer pain,”
The Journal of Pain, vol. 10, no. 2, pp. 113.e22–130.e22, 2009.
[8] CDC guidelines for Prescribing Opioids for Chronic Pain—
United States, 2016.
[9] J. van Amsterdam and W. van den Brink, “The misuse of
prescription opioids: A threat for Europe?” Current Drug Abuse
Reviews, vol. 8, no. 1, pp. 3–14, 2015.
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